Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Influence of "GERD" label on parents' decision to medicate infants.

Scherer LD, Zikmund-Fisher BJ, Fagerlin A, Tarini BA.

Pediatrics. 2013 May;131(5):839-45. doi: 10.1542/peds.2012-3070.

2.

The hazards of medicalizing variants of normal.

Carey WB.

Pediatrics. 2013 May;131(5):991-2. doi: 10.1542/peds.2013-0286. No abstract available.

3.

Gastroesophageal reflux: management guidance for the pediatrician.

Lightdale JR, Gremse DA; Section on Gastroenterology, Hepatology, and Nutrition..

Pediatrics. 2013 May;131(5):e1684-95. doi: 10.1542/peds.2013-0421. Review.

4.

Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review.

van der Pol RJ, Smits MJ, van Wijk MP, Omari TI, Tabbers MM, Benninga MA.

Pediatrics. 2011 May;127(5):925-35. doi: 10.1542/peds.2010-2719. Review.

PMID:
21464183
5.

Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease.

Higginbotham TW.

Ann Pharmacother. 2010 Mar;44(3):572-6. doi: 10.1345/aph.1M519. Review.

PMID:
20124466
6.

Assessing the impact of lifestyle modification education on knowledge and behavior changes in gastroesophageal reflux disease patients on proton pump inhibitors.

Finley K, Giannamore M, Bennett M, Hall L.

J Am Pharm Assoc (2003). 2009 Jul-Aug;49(4):544-8. doi: 10.1331/JAPhA.2009.08004.

PMID:
19589767
7.

Gastroesophageal reflux disease: exaggerations, evidence and clinical practice.

Ferreira CT, Carvalho Ed, Sdepanian VL, Morais MB, Vieira MC, Silva LR.

J Pediatr (Rio J). 2014 Mar-Apr;90(2):105-18. doi: 10.1016/j.jped.2013.05.009. Review.

8.

Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients.

Davidson G, Wenzl TG, Thomson M, Omari T, Barker P, Lundborg P, Illueca M.

J Pediatr. 2013 Sep;163(3):692-8.e1-2. doi: 10.1016/j.jpeds.2013.05.007.

PMID:
23800403
9.

Safety and pharmacodynamics of lansoprazole in patients with gastroesophageal reflux disease aged <1 year.

Springer M, Atkinson S, North J, Raanan M.

Paediatr Drugs. 2008;10(4):255-63.

PMID:
18590344
10.

Lower esophageal sphincter injections for the treatment of gastroesophageal reflux disease.

Watson TJ, Peters JH.

Thorac Surg Clin. 2005 Aug;15(3):405-15. Review.

PMID:
16104131
11.

Predictive modelling: parents' decision making to use online child health information to increase their understanding and/or diagnose or treat their child's health.

Walsh AM, Hyde MK, Hamilton K, White KM.

BMC Med Inform Decis Mak. 2012 Dec 10;12:144. doi: 10.1186/1472-6947-12-144.

12.

Mealtime-related dosing directions for proton-pump inhibitors in gastroesophageal reflux disease: physician knowledge, patient adherence.

Solem C, Mody R, Stephens J, Macahilig C, Gao X.

J Am Pharm Assoc (2003). 2014 Mar-Apr;54(2):144-53. doi: 10.1331/JAPhA.2014.13117.

PMID:
24632930
13.
14.
15.

Look--but also listen! ReQuest: an essay on a new validated scale to assess the outcome of GERD treatment.

Bardhan KD, Berghöfer P.

Digestion. 2007;75 Suppl 1:87-100. Review.

PMID:
17489037
16.

Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age.

Sandström M, Davidson G, Tolia V, Sullivan JE, Långström G, Lundborg P, Brown K.

Clin Ther. 2012 Aug;34(8):1828-38. doi: 10.1016/j.clinthera.2012.06.028.

PMID:
22832034
18.

Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD.

Hussain S, Kierkus J, Hu P, Hoffman D, Lekich R, Sloan S, Treem W.

J Pediatr Gastroenterol Nutr. 2014 Feb;58(2):226-36. doi: 10.1097/MPG.0000000000000195.

PMID:
24121146
19.

Gastroesophageal reflux disease symptom severity, proton pump inhibitor use, and esophageal carcinogenesis.

Nason KS, Wichienkuer PP, Awais O, Schuchert MJ, Luketich JD, O'Rourke RW, Hunter JG, Morris CD, Jobe BA.

Arch Surg. 2011 Jul;146(7):851-8. doi: 10.1001/archsurg.2011.174.

20.

Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease.

Bytzer P, Jones R, Vakil N, Junghard O, Lind T, Wernersson B, Dent J.

Clin Gastroenterol Hepatol. 2012 Dec;10(12):1360-6. doi: 10.1016/j.cgh.2012.06.030.

PMID:
22813439
Items per page

Supplemental Content

Support Center